000836178 001__ 836178
000836178 005__ 20220930130128.0
000836178 0247_ $$2doi$$a10.1002/jnr.24110
000836178 0247_ $$2ISSN$$a0360-4012
000836178 0247_ $$2ISSN$$a1097-4547
000836178 0247_ $$2pmid$$apmid:28695985
000836178 0247_ $$2WOS$$aWOS:000425811000009
000836178 0247_ $$2altmetric$$aaltmetric:23450471
000836178 037__ $$aFZJ-2017-05301
000836178 082__ $$a570
000836178 1001_ $$0P:(DE-Juel1)131711$$aWedekind, Franziska$$b0$$eCorresponding author
000836178 245__ $$aIntrastriatal administration of botulinum neurotoxin A normalizes striatal D$_{2}$R binding and reduces striatal D$_{1}$R binding in male hemiparkinsonian rats
000836178 260__ $$aNew York, NY [u.a.]$$bWiley-Liss$$c2018
000836178 3367_ $$2DRIVER$$aarticle
000836178 3367_ $$2DataCite$$aOutput Types/Journal article
000836178 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1517838759_21914
000836178 3367_ $$2BibTeX$$aARTICLE
000836178 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000836178 3367_ $$00$$2EndNote$$aJournal Article
000836178 520__ $$aCerebral administration of botulinum neurotoxin A (BoNT-A) has been shown to improve disease-specific motor behavior in a rat model of Parkinson disease (PD). Since the dopaminergic system of the basal ganglia fundamentally contributes to motor function, we investigated the impact of BoNT-A on striatal dopamine receptor expression using in vitro and in vivo imaging techniques (positron emission tomography and quantitative autoradiography, respectively). Seventeen male Wistar rats were unilaterally lesioned with 6-hydroxydopamine (6-OHDA) and assigned to two treatment groups 7 weeks later: 10 rats were treated ipsilaterally with an intrastriatal injection of 1 ng BoNT-A, while the others received vehicle (n = 7). All animals were tested for asymmetric motor behavior (apomorphine-induced rotations and forelimb usage) and for striatal expression of dopamine receptors and transporters (D1 R, D2 R, and DAT). The striatal D2 R availability was also quantified longitudinally (1.5, 3, and 5 months after intervention) in 5 animals per treatment group. The 6-OHDA lesion alone induced a unilateral PD-like phenotype and a 13% increase of striatal D2 R. BoNT-A treatment reduced the asymmetry in both apomorphine-induced rotational behavior and D2 R expression, with the latter returning to normal values 5 months after intervention. D1 R expression was significantly reduced, while DAT concentrations showed no alteration. Independent of the treatment, higher interhemispheric symmetry in raclopride binding to D2 R was generally associated with reduced forelimb akinesia. Our findings indicate that striatal BoNT-A treatment diminishes motor impairment and induces changes in D1 and D2 binding site density in the 6-OHDA rat model of PD.
000836178 536__ $$0G:(DE-HGF)POF3-571$$a571 - Connectivity and Activity (POF3-571)$$cPOF3-571$$fPOF III$$x0
000836178 588__ $$aDataset connected to CrossRef
000836178 7001_ $$0P:(DE-Juel1)131712$$aOskamp, Angela$$b1
000836178 7001_ $$0P:(DE-Juel1)131831$$aLang, Markus$$b2
000836178 7001_ $$0P:(DE-HGF)0$$aHawlitschka, Alexander$$b3
000836178 7001_ $$0P:(DE-Juel1)131714$$aZilles, Karl$$b4
000836178 7001_ $$0P:(DE-HGF)0$$aWree, Andreas$$b5
000836178 7001_ $$0P:(DE-Juel1)131672$$aBauer, Andreas$$b6
000836178 773__ $$0PERI:(DE-600)1474904-x$$a10.1002/jnr.24110$$n1$$p75–86$$tJournal of neuroscience research$$v96$$x0360-4012$$y2018
000836178 8564_ $$uhttps://juser.fz-juelich.de/record/836178/files/JuSER%20-%20Wedekind.pdf$$yRestricted
000836178 8564_ $$uhttps://juser.fz-juelich.de/record/836178/files/JuSER%20-%20Wedekind.pdf?subformat=pdfa$$xpdfa$$yRestricted
000836178 8767_ $$88892662$$92017-11-14$$d2017-11-15$$eColour charges$$jZahlung erfolgt$$zUSD 1500,-
000836178 909CO $$ooai:juser.fz-juelich.de:836178$$pOpenAPC$$pVDB$$popenCost
000836178 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131711$$aForschungszentrum Jülich$$b0$$kFZJ
000836178 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131712$$aForschungszentrum Jülich$$b1$$kFZJ
000836178 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131831$$aForschungszentrum Jülich$$b2$$kFZJ
000836178 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131714$$aForschungszentrum Jülich$$b4$$kFZJ
000836178 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131672$$aForschungszentrum Jülich$$b6$$kFZJ
000836178 9131_ $$0G:(DE-HGF)POF3-571$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$vConnectivity and Activity$$x0
000836178 9141_ $$y2017
000836178 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000836178 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NEUROSCI RES : 2015
000836178 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000836178 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000836178 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000836178 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000836178 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000836178 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000836178 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000836178 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000836178 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000836178 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000836178 920__ $$lyes
000836178 9201_ $$0I:(DE-Juel1)INM-2-20090406$$kINM-2$$lMolekulare Organisation des Gehirns$$x0
000836178 9201_ $$0I:(DE-Juel1)INM-1-20090406$$kINM-1$$lStrukturelle und funktionelle Organisation des Gehirns$$x1
000836178 9201_ $$0I:(DE-Juel1)INM-5-20090406$$kINM-5$$lNuklearchemie$$x2
000836178 980__ $$ajournal
000836178 980__ $$aVDB
000836178 980__ $$aI:(DE-Juel1)INM-2-20090406
000836178 980__ $$aI:(DE-Juel1)INM-1-20090406
000836178 980__ $$aI:(DE-Juel1)INM-5-20090406
000836178 980__ $$aAPC
000836178 980__ $$aUNRESTRICTED
000836178 9801_ $$aAPC